Cargando…
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
Interleukin-12 (IL-12) is a potent cytokine that may be harnessed to treat cancer. To date, nearly 100 IL-12-based clinical trials have been initiated worldwide. Yet systemic administration of IL-12 is toxic. Different strategies are being developed to reduce such toxicities by restricting IL-12 dis...
Autores principales: | Huang, Ju, Liu, Yuanfeng, Au, Bryan C, Barber, Dwayne L, Arruda, Andrea, Schambach, Axel, Rothe, Michael, Minden, Mark D, Paige, Christopher J, Medin, Jeffrey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142463/ https://www.ncbi.nlm.nih.gov/pubmed/27933304 http://dx.doi.org/10.1038/mtm.2016.74 |
Ejemplares similares
-
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019) -
CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017) -
Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023) -
Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model
por: Berger, Alexandra, et al.
Publicado: (2019) -
Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)